1. Home
  2. ARDX vs LXRX Comparison

ARDX vs LXRX Comparison

Compare ARDX & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

SELL

Current Price

$3.24

Market Cap

862.3M

Sector

Health Care

ML Signal

SELL

LXRX

Lexicon Pharmaceuticals Inc.

HOLD

Current Price

$1.62

Market Cap

996.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARDX
LXRX
Founded
2007
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
862.3M
996.7M
IPO Year
2014
2000

Fundamental Metrics

Financial Performance
Metric
ARDX
LXRX
Price
$3.24
$1.62
Analyst Decision
Strong Buy
Buy
Analyst Count
11
6
Target Price
★ $12.90
$4.55
AVG Volume (30 Days)
★ 4.1M
2.9M
Earning Date
10-29-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 77.78
EPS
N/A
★ N/A
Revenue
$2,607,000.00
★ $49,803,000.00
Revenue This Year
$19.98
N/A
Revenue Next Year
$27.70
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 60.24
52 Week Low
$3.18
$1.10
52 Week High
$8.40
$2.68

Technical Indicators

Market Signals
Indicator
ARDX
LXRX
Relative Strength Index (RSI) 29.24 27.35
Support Level N/A $1.50
Resistance Level $3.63 $1.81
Average True Range (ATR) 0.11 0.11
MACD 0.01 -0.01
Stochastic Oscillator 12.50 1.79

Price Performance

Historical Comparison
ARDX
LXRX

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Share on Social Networks: